Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice: Cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals

Cancer Research

Volumn 56, Issue 15, 1996, Pages 3597-3604

  Shapiro, Richard L ^a,b   Duquette, Julie G ^a   Roses, Daniel F ^a   Nunes, Irene ^a,b   Harris, Matthew N ^a   Kamino, Hideko ^a   Wilson, E Lynette ^a,b   Rifkin, Daniel B ^a,b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLUE NEVUS; CANCER INVASION; CARCINOGENESIS; ENZYME INDUCTION; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; LYMPHATIC METASTASIS; MELANOCYTES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEVUS, BLUE; SKIN NEOPLASMS; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 0029682495     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Testa, J. E., and Quigley, J. P. The role of urokinase-type plasminogen activator in aggressive tumor cell behavior. Cancer Metastasis Rev., 9: 101-112, 1990.
2. Ossowski, L. In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface bound urokinase. J. Cell. Biol., 107: 2437-2445, 1988.
3. Kwaan, H. C. The plasminogen activator system in malignancy. Cancer Metastasis Rev., 11: 291-311, 1992.
4. Danø, K., Andreasen, P. A., Grøndahl-Hansen, J., Kristensen, P., Nielson, L. S., and Skirver, L. Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 44: 139-266, 1985.
5. Plow, E. F., Freaney, D. E., Plescia, J., and Miles, L. A. The plasminogen activator system and cell surface: evidence for plasminogen and urokinase receptors on the same cell line. J. Cell. Biol., 103: 2411-2420, 1986.
6. Moscatelli, D., and Rifkin, D. B. Membrane and matrix localization of proteases: a common theme in tumor cell invasion and angiogenesis. Biochim. Biophys. Acta, 948: 67-85, 1988.
7. Murphy, G., Reynolds, J. J., and Hembry, R. M. Metalloproteases and cancer invasion and metastasis. Int. J. Cancer, 44: 757-760, 1989.
8. Saksela, O., and Rifkin, D. B. Cell-associated plasminogen activation: regulation and physiological functions. Annu. Rev. Cell. Biol., 4: 93-126, 1988.
9. Liotta, L. A., Tryggvason, S., Garbisa, S., Hart, I., Foltz, C. M., and Shafie, S. Metastatic propensity correlates with tumor cell degradation of basement membrane collagen. Nature (Lond.), 284: 67-68, 1980.
10. Montgomery, A. M. P., De Clerck, Y. A., Langley, K. E., Reisfeld, R. A., and Mueller, B. M. Melanoma-mediated dissolution of extracellular matrix contribution of urokinase-dependent and metalloprotease-dependent proteolytic pathways. Cancer Res., 53: 693-700, 1993.
11. Liotta, L. A. Tumor invasion and metastasis - role of the extracellular matrix. Cancer Res., 46: 1-7, 1986.
12. Janicke, F., Pache, L., Schmitt, M., Ulm, K., Thomssen, C., Prechtl, A., and Graeff, H. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type I Cancer Res., 54: 2527-2530, 1994.
13. Ganesh, S., Sier, C. F. M., Griffoen, G., Vloedgraven, H. J. M., de Boer, A., Welvaart, K., van de Velde, C. J. H., van Krieken, J. H. J. M., Verheijen, J. H., Lamers, C. B. H. W., and Verspaget, H. W. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res., 54: 4065-4071, 1994.
14. Pedersen, H., Brunner, N., Francis, D., Osterlind, K., Rønne, E., Hansen, H. H., Danø, K., and Grøndahl-Hansen, J. Prognostic impact of urokinase, urokinase receptor, and type I plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res., 54: 4671-4675, 1994.
15. Nekarda, H., Schmitt, M., Ulm, K., Wenninger, A., Vogelsang, H., Becker, K., Roder, J. D., Fink, U., and Stewert, J. R. Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res., 54: 2900-2907, 1994.
16. Achbarou, A., Kaiser, S., Tremblay, G., Ste-Marie, L-G., Brodt, P., Goltzman, D., and Rabbani, S. A. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. Cancer Res., 54: 2372-2377, 1994.
17. Yamamoto, M., Sawaya, R., Mohanam, S., Rao, V. H., Bruner, J. M., Nicolson, G. L., and Rao, J. S. Expression and localization of urokinase-type plasminogen activator receptor in human gliomas Cancer Res., 54: 5016-5020, 1994.
18. Delbaldo, C., Masouye, I., Sauret, J-H., Vassalli, J-D., and Sappino, A-P. Plasminogen activation in melanocytic neoplasia. Cancer Res., 54: 4547-4552, 1994.
19. Markus, G. The relevance of plasminogen activators to neoplastic growth. A recent review of the literature. Enzyme (Basel), 40: 158-172, 1988.
20. Stahl, A., and Mueller, B. M. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res., 54: 3066-3071, 1994.
21. Meissauer, A., Kramer, M. D., Schirrmacher, V., and Brunner, G. Generation of cell surface-bound plasmin by cell associated urokinase type or secreted tissue-type plasminogen activator a key event in melanoma cell invasiveness in vitro. Exp. Cell Res., 199: 179-190, 1992.
22. Sordat, B., Reiter, L., and Cajot, J-F. Modulation of the malignant phenotype with the urokinase-type plasminogen activator and the type 1 plasminogen activator inhibitor. Cell Differ. Dev., 32: 277-286, 1990.
23. Hearing, V. J., Law, L. W., Corti, A., Appella, E., and Blasi, F. Modulation of metastatic potential by cell surface urokinase of murine melanoma cells Cancer Res., 48: 1270-1278, 1988.
24. Vassalli, J., and Belin, D. Amiloride selectively inhibits the urokinase-type plasminogen activator FEBS Lett., 214: 187-193, 1987.
25. Towle, M. J., Lee, A., Maduakor, E. C., Schwartz, C. E., Bridges, A. J., and Littlefield, B. A. Inhibition of urokinase by 4-substituted benzo(b)thiophene-2-carboxamidines: an important new class of selective synthetic urokinase inhibitor. Cancer Res., 53: 2553-2559, 1993.
26. Ossowski, L., and Reich, E. Antibodies to plasminogen activator inhibit human tumor metastasis Cell, 52: 321-328, 1983.
27. Ossowski, L., Russo-Payne, H., and Wilson, E. L. Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. Cancer Res., 51: 274-281, 1991.
28. Yu, H., and Schultz, R. M. Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B16 cells transfected with human urokinase sense and antisense genes. Cancer Res., 50: 7623-7633, 1990.
29. Mayer, M. Biochemical and biological aspects of the plasminogen activator system. Clin. Biochem., 23: 197-211, 1990.
30. Fidler, I. J. Biological behavior of malignant melanoma cells correlated to their survival in vivo. Cancer Res., 35: 218-224, 1975.
31. Qian, F., Bajkowski, A. S., Steiner, D. F., Chan, S. J., and Frankfater, A. Expression of five cathepsins in murine melanomas of varying metastatic potential and normal tissues. Cancer Res., 49: 4870-4875, 1989.
32. Fidler, I. J. Critical factors in the biology of human cancer metastasis: twenty-eighth GHA Clowes Memorial Award Lecture. Cancer Res., 50: 6130-6138, 1990.
33. Fodstad, O. and Kjonniksen I. Microenvironment revisited: time for reappraisal of some prevailing concepts of cancer metastasis J. Cell. Biochem., 56: 23-28, 1994.
34. Fodstad, O., Aamdal, S., McMenamin, M., Nesland, J. M., and Pihl, A. A new experimental metastasis model in athymic nude mice: the human melanoma LOX Int. J. Cancer, 41: 442-449, 1988.
35. Hoffman, R. M. Orthotopic is orthodox why are orthotopic-transplant models different from all other models? J. Cell. Biochem., 56: 1-3, 1994.
36. Fidler, I. J. Selection of successive tumor lines for metastasis. Nature (Lond.), 242: 148-149, 1973.
37. Kubota, K. Metastatic models of human cancer xenografted in the nude mouse: the importance of orthotopic transplantation. J. Cell. Biochem., 56: 4-8, 1994.
38. Carmeliet, P., Schoonjans, L., Kieckens, L., Ream, B., Degen, J., Bronson, R., De Vos, R., van den Oord, J. J., Collen, D., and Mulligan, R. C. Physiological consequences of loss of plasminogen activator gene function in mice. Nature (Lond.), 368: 419-424, 1994.
39. Clark, W. H., Jr., Min, B. H., and Kligman, L. H. L. The developmental biology of induced malignant melanoma in guinea pigs and a comparison with other neoplastic systems. Cancer Res., 36: 4079-4091, 1976.
40. Berkelhammer, J., Oxenhandler, R. W., Hook, R. R., Jr., and Hennessy, J. M. Development of a new melanoma model in C57BL/6 mice. Cancer Res., 42: 3157-3163, 1982.
41. Berkelhammer, J., and Oxenhandler, R. W. Evaluation of premalignant and malignant lesions during the induction of mouse melanomas. Cancer Res., 47: 1251-1254, 1987.
42. Takizawa, H., Sato S-i., Kitajima, H., Konishi, S., Iwata, K., and Hayashi, Y. Mouse skin melanoma induced in two stage chemical carcinogenesis with 7,12-dimethylbenz(a)anthracene and croton oil. Carcinogenesis (Lond.), 6: 921-923, 1983.
43. Gross, J. L., Moscatelli, D., Jaffe, E. A., and Rifkin, D. B. Plasminogen activator and collagenase production by cultured capillary endothelial cells. J. Cell. Biol., 95: 974-981, 1982.
44. Breslow, A. Thickness, cross-sectional area, and the depth of invasion in the prognosis of cutaneous melanoma. Ann. Surg., 172: 902-908, 1970.
45. Nakajima, T., Watanabe, S., and Sato, Y. Immunohistochemical demonstration of S-100 protein in malignant melanoma and pigmented nevus and its diagnostic application Cancer (Phila.), 50: 912-918, 1982.
46. Rodriguez, H. A., and Ackerman, L. V. Cellular blue nevus Clinicopathologic study of forty-five cases. Cancer (Phila.), 21: 393-412, 1968.
47. Gruber, S. B., Barnhill, R. L., Stenn, K. S., and Roush, G. C. Nevomelanocytic proliferations in association with cutaneous melanoma: a multivariate analysis J. Am. Acad. Dermatol., 21: 773-776, 1989.
48. Ashman, L. K., Murray, A. W., Cook, M. G., and Kotlarski, I. Two stage carcinogenesis in sensitive and resistant mouse strains Carcinogenesis (Lond.), 3: 99-102, 1982.
49. Naito, M., Naito, Y., and DiGiovanni, J. Comparison of histological changes in the skin of DBA/2 and C57BL/6 mice following exposure to various promoting agents. Carcinogenesis (Lond.), 8: 1807-1815, 1987.
50. Reiners, J. J., Jr., Nesnow, S., and Slaga, T. J. Murine susceptibility to two-stage skin carcinogenesis is influenced by the agent used for promotion Carcinogenesis (Lond.), 5: 301-305, 1984.
51. 2 by macrophages (Mφ), and the sensitivity to the promotion of skin tumors by phorbol esters (PE) Proc. Am. Assoc. Cancer Res., 27: 146, 1986.
52. Lewis, J. G., and Adams, D. O. Enhanced release of hydrogen peroxide and metabolites of arachidonic acid by macrophages from SENCAR truce following stimulation with phorbol esters. Cancer Res., 46: 5696-5700, 1986.
53. Fischer, S. J., Baldwin, J. K., and Adams, L. M. Effects of anti-promoters and strain of mouse on tumor promoter-induced oxidants in murine epidermal cells. Carcinogenesis (Lond.), 7: 915-918, 1986.
54. de Vanes, T. J., Kitson, J. L., Silvers, W. K., and Mintz, B. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice. Cancer Res., 55: 4681-4687, 1995.
55. Saksela, O., and Rifkin, D. B. Release of basic fibroblast growth factor-heparin sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity. J. Cell. Biol., 105: 957-963, 1990.
56. Sato, Y., and Rifkin, D. B. Inhibition of endothelial cell movement by pericytes and smooth muscle cells: activation of a latent transforming growth factor β-1-like molecule by plasmin J. Cell. Biol., 109: 309-315, 1989.
57. Naldini, L., Tamagnone, L., Vigna, E., Sachs, M., Hartmann, G., Birchmeier, W., Daikuhara, Y., Tsubouchi, H., Blasi, F., and Comoglio, P. M. Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J., 11: 4825-4833, 1992.
58. Halaban, R., Ghosh, S., and Baird, A. bFGF is the putative natural growth factor for human melanocytes. In Vitro Cell & Dev. Biol., 23: 47-52, 1987.
59. Rifkin, D. B., Moscatelli, D., Bizik, J., Quarto, N., Blei, F., Dennis, P., Flaumenhaft, R., and Mignatti, P. Growth factor control of extracellular proteoiysis. Cell Differ. Dev., 32: 313-318, 1990.
60. Moscatelli, D., Presta, M., and Rifkin, D. B. Purification of a factor from human placenta that stimulates capillary endothelial cell protease production, DNA synthesis and migration Proc. Natl. Acad. Sci. USA, 83: 2091-2095, 1986.